Novo Nordisk | NVO - Gross Profit On Sales



Novo Nordisk reported DKK65.2B in Gross Profit on Sales for its fiscal quarter ending in March of 2025.


Gross Profit On Sales Change Date
ANI Pharmaceuticals USD 113.48M 10.61M Jun/2025
Aurora Cannabis CAD 27.95M 18.6M Jun/2025
Bausch Health Companies USD 1.77B 208M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Canopy Growth CAD 18.04M 6.06M Jun/2025
Corcept Therapeutics USD 191M 36.19M Jun/2025
Drreddys Laboratories INR 48.63B 425M Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
Merck USD 12.99B 224M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Novo Nordisk 64.01B 1.19B Jun/2025
Novo Nordisk DKK 65.2B 5.19B Mar/2025
Pacira USD 125.91M 8.71M Jun/2025
Perrigo USD 362.9M 29.4M Jun/2025
Prestige Brands USD 140.33M 29.68M Jun/2025
Sanofi EUR 7.74B 26M Jun/2025
Supernus Pharmaceuticals USD 127.81M 6.25M Jun/2025
Zoetis USD 1.78B 180M Jun/2025